Výsledky vyhledávání

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

Autor: S. Duncil, R. Baumhefner, V. Gausche, L. Tvardek, G. Shifroni, E. Cerreta, S. Remo, J. H. Parnell, D. Lefkowitz, S. J. Bird, L. Needham, B. Borowski, M. Shepard, Y. Stark, S. Craig, L. Pardo, T. Vollmer, E. Katz, G. W. Ellison, C Jr Bever, A. C. Tselis, R. Grossman, P. M. Colletti, S. R. Schwid, I. Pinchasi, M. Singh, Staley A. Brod, W. Badger, Andrew D. Goodman, J. B. Guarnaccia, A. Gudusky, H. Panitch, M. A. Burns, J. Tsuruda, Jerry S. Wolinsky, J. W. Rose, D. Lisak, M. Gorbova, C. J. Becker, L. P. Weiner, E. W C Kwok, Dennis L. Kolson, B. Peters, C. Kawai, J. W. Lindsey, N. Carr, I. Vainrub, R. Misnick, K. McCarthy, R. Lewis, M. D. Petrie, J. Flemming, M. Viswanathan, C. Halvorson, K. P. Johnson, P. Turski, G. Sze, O. Khan, B. R. Brooks, D. Ladkani, D. Pfohl, A. Wallace, K. Martin, A. A. Pruitt, Francisco Gonzalez-Scarano, Ponnada A. Narayana, J. Kamholtz, R. Padilla, R. P. Lisak, L. Mannon, S. Kadosh, C. C. Ford, K. Conway, G. Hunter, S. Bhat, S. Jalbut, L. Medina, L. Rosner, L. W. Myers, G. Moore, J. B. Burns, S. Sinha, E. Greinel, J. Garbern, D. A. Shrier, M. Boykins, J. R. Bentson, N. Kachuck, M. Nessaiver

Publikováno v: Multiple Sclerosis. 7:33-41

After the placebo-controlled extension of the pivotal US trial of glatiramer acetate for the treatment of relapsing multiple sclerosis ended, 208 participants entered an open-label, long-term treatment protocol. Magnetic resonance imaging (MRI) was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0a63205d214a1f405d85fd63875403c
https://doi.org/10.1191/135245801667520627

Zobrazit plný text záznamu

Alfacalcidol (alpha D3) and calcium in osteoporosis

Autor: J, Menczel, J, Foldes, R, Steinberg, I, Leichter, B, Shalita, T, Bdolah-Abram, S, Kadosh, Z, Mazor, D, Ladkani

Publikováno v: Clinical orthopaedics and related research. (300)

In a prospective, randomized study, 66 osteoporotic postmenopausal women (mean age, 67 years) were scheduled to receive either alfacalcidol 0.25 microgram twice daily together with calcium 500 mg twice daily (treatment group, n = 24) or placebo twice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::767038648e4978bec6ba59d9d1946d4c
https://pubmed.ncbi.nlm.nih.gov/8131343

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání